amoxicillin + clavulanic acid + lactic acid bacillus

Amclue LB is an oral fixed-dose combination antibiotic and probiotic formulation developed by Goldline Pharmaceutical. It contains amoxicillin (a broad-spectrum penicillin antibiotic), clavulanic acid (a beta-lactamase inhibitor), and lactic acid bacillus (a probiotic). Amoxicillin works by binding to and inhibiting penicillin-binding proteins (PBPs), which disrupts bacterial cell wall synthesis and leads to cell lysis. Clavulanic acid prevents the enzymatic degradation of amoxicillin by inhibiting bacterial beta-lactamases, thereby overcoming resistance and extending the antibacterial spectrum. Lactic acid bacillus is included to restore and maintain healthy gut microbiota, reducing the risk of antibiotic-associated diarrhea. Amclue LB is approved and marketed in India for the treatment of various susceptible bacterial infections, including respiratory tract, urinary tract, skin, and soft tissue infections.

Brand names

Amclue 625 LBAmclue625 LBAmclue-625 LBAmclue LBAmclue LB 625

Other names

amoxicillin + clavulanate + lactic acid bacillusamoxicillin + clavulanic acid + lactic acid bacillusamoxicillin + clavulanic acid + lactobacillusamoxicillin + clavulanic acid + lactobacillus sporogenesamoxycillin + clavulanate + lactic acid bacillusamoxycillin + clavulanic acid + lactic acid bacillusamoxycillin + clavulanic acid + lactobacillusamoxycillin + clavulanic acid + lactobacillus sporogenesco-amoxyclav + lactic acid bacillusco-amoxyclav + lactobacillus